12:00 AM
 | 
Mar 30, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Allovectin-7: Phase III ongoing

For the second time, a DSMB recommended continuation of the single-blind, U.S. Phase III AIMM trial in about 375 chemotherapy-naïve patients based on a review of safety data. Vical has an SPA from FDA for...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >